Kenya Lung Cancer Therapeutics Market Report 2022 to 2030

Kenya Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Kenya Lung Cancer Therapeutics Market will reach a value of $396 Mn from $194 Mn in 2022, growing at a CAGR of 9.3% during 2022-2030. The Lung Cancer Therapeutics Market in Kenya is dominated by a few domestic pharmaceutical companies such as Universal Corporation Limited, Cosmos Limited, and Avenue Healthcare. The Lung Cancer Therapeutics Market in Kenya is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Kenya lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.l

ID: IN10KEPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Vishwa Modhia

Buy Now

Kenya Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Kenya Lung Cancer Therapeutics market will reach a value of $396 Mn from $194 Mn in 2022, growing at a CAGR of 9.3% during 2022-2030.

Kenya is a lower middle-income, developing country in Eastern Africa bordering the Indian Ocean and Lake Victoria. Lung cancer incidence rates in Kenya are 3.6 for males and 2.3 for females. Male smoking prevalence is 15%, whereas female smoking prevalence is 1%. Kenya has 0.2 radiation machines per 1,000 cancer patients. In 2017, the proportion of Kenyans utilising solid fuels was 80%, resulting in indoor pollution. The National Cancer Institute of Kenya was founded in accordance with the Cancer Prevention and Control Act No. 15 of 2012.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Kenya reached 669 or 0.25% of total deaths. The age-adjusted Death Rate is 3.20 per 100,000 population ranks Kenya 156^th in the world. Kenya's government spends 4.6% of its GDP on healthcare.

Kenya Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Eldoret Cancer Registry (ECR) provides statistics and epidemiologic profiles for Kenya's western area. The majority of lung cancer cases occur between the ages of 50 and 79, which could be attributable to the slow disease progression and delays in early diagnosis. Males had higher rates, which may be connected to susceptibility to risk factors such as smoking and industrial pollutants. These aspects could boost Kenya's Lung Cancer Therapeutics market.

Market Restraints

Kenya has few cancer treatment facilities, with the primary one being Kenyatta National Hospital (KNH) in the public sector. This endangers the lives of thousands of cancer patients in Kenya who are unable to receive treatment at KNH's three operable radiotherapy equipment. Although cancer is treatable, 70-80 % of people diagnosed with cancer in Kenya are in advanced stages, with a high rate of misdiagnosis and insufficient screening preventing early identification. Due to complexities in screening and testing techniques, a lung cancer diagnosis has proven difficult in western Kenya. The adult population's burden is mainly unknown because most patients are treated for pulmonary tuberculosis, which has comparable clinical signs. These factors may deter new entrants into the Kenya Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Universal Corporation Limited: Universal Corporation is a Kenyan pharmaceutical company that specializes in the production and distribution of generic medicines. The company offers a range of lung cancer treatments including chemotherapy drugs
Cosmos Limited: Cosmos Limited is a Kenyan pharmaceutical company that specializes in the production and distribution of generic medicines. The company offers a range of lung cancer treatments including chemotherapy drugs
Avenue Healthcare: Avenue Healthcare is a Kenyan healthcare company that operates a number of clinics and hospitals in the country. The company offers a range of cancer treatments including chemotherapy drugs
Medisel Kenya Limited: Medisel Kenya is a Kenyan pharmaceutical company that specializes in the distribution of pharmaceutical products
Zawadi Healthcare: Zawadi Healthcare is a Kenyan healthcare company that operates a number of clinics in the country

Healthcare Policies and Reimbursement Scenarios

The Pharmacy and Poisons Board (PPB) is the regulatory authority in Kenya responsible for the approval and regulation of therapeutic items, including lung cancer therapies. The Pharmacy and Poisons Board is Kenya's Drug Regulatory Authority, formed by the Pharmacy and Poisons Act, Chapter 244 of the Kenyan Laws. The Board of Pharmacy supervises the practice of pharmacy as well as the manufacture and sale of medications and poisons.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.